title: Evaluation of nanoparticle immunotoxicity.
abstract: The pharmaceutical industry is developing increasing numbers of drugs and diagnostics based on nanoparticles, and evaluating the immune response to these diverse formulations has become a challenge for scientists and regulatory agencies alike. An international panel of scientists and representatives from various agencies and companies reviewed the imitations of current tests at a workshop held at the National Cancer Institute in Frederick, Maryland. This article outlines practical strategies for identifying and controlling interferences in common evaluation methods and the implications for regulation.
authors: Nanotechnology Characterization Laboratory, SAIC-Frederick Inc., NCI-Frederick, Frederick, Maryland 21702, USA. marina@mail.nih.gov
authors: Marina A
authors: MA
authors: Dobrovolskaia
authors: Dori R
authors: DR
authors: Germolec
authors: James L
authors: JL
authors: Weaver
mesh_terms: D019411:Clinical Laboratory Techniques / Q000592:standards; D004345:Drug Industry / Q000592:standards; D000922:Immunotoxins / Q000633:toxicity; D008033:Limulus Test; D053758:Nanoparticles / Q000633:toxicity*; D018675:Toxicity Tests / Q000379:methods* / Q000592:standards
chemical_list: D000922:Immunotoxins